125 related articles for article (PubMed ID: 36403281)
21. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
[TBL] [Abstract][Full Text] [Related]
22. ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.
Wu M; Zhou Y; Fei C; Chen T; Yin X; Zhang L; Ren Z
Int J Oncol; 2020 Sep; 57(3):845-857. PubMed ID: 32705157
[TBL] [Abstract][Full Text] [Related]
23. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500
[TBL] [Abstract][Full Text] [Related]
24. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-216b suppresses the cell growth of hepatocellular carcinoma by inhibiting Ubiquitin-specific peptidase 28 expression.
Zhang JF
Kaohsiung J Med Sci; 2020 Jun; 36(6):423-428. PubMed ID: 32053284
[TBL] [Abstract][Full Text] [Related]
26. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
27. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.
Li J; Li MH; Wang TT; Liu XN; Zhu XT; Dai YZ; Zhai KC; Liu YD; Lin JL; Ge RL; Sun SH; Wang F; Yuan JH
Br J Cancer; 2021 Sep; 125(6):865-876. PubMed ID: 34274945
[TBL] [Abstract][Full Text] [Related]
28. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
Tu K; Zheng X; Zhou Z; Li C; Zhang J; Gao J; Yao Y; Liu Q
PLoS One; 2013; 8(7):e68574. PubMed ID: 23840897
[TBL] [Abstract][Full Text] [Related]
30. A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma.
Guo C; Gao C; Zhao D; Li J; Wang J; Sun X; Liu Q; Hao L; Greenaway FT; Tian Y; Liu S; Sun MZ
J Exp Clin Cancer Res; 2020 Apr; 39(1):70. PubMed ID: 32326970
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
32. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
33. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
34. Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/β-Catenin Signaling.
Tong Z; Li M; Wang W; Mo P; Yu L; Liu K; Ren W; Li W; Zhang H; Xu J; Yu C
J Biol Chem; 2015 Jul; 290(30):18596-608. PubMed ID: 26082485
[TBL] [Abstract][Full Text] [Related]
35. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.
Tao L; Li D; Mu S; Tian G; Yan G
Lab Invest; 2022 May; 102(5):494-504. PubMed ID: 35264707
[TBL] [Abstract][Full Text] [Related]
36. A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma.
Liu D; Dong L; Liu Y; Wen D; Gao D; Sun H; Fan J; Wu W
Tumour Biol; 2016 Apr; 37(4):5039-47. PubMed ID: 26546431
[TBL] [Abstract][Full Text] [Related]
37. FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC.
Kim KM; Park SH; Bae JS; Noh SJ; Tao GZ; Kim JR; Kwon KS; Park HS; Park BH; Lee H; Chung MJ; Moon WS; Sylvester KG; Jang KY
Sci Rep; 2017 Jun; 7(1):3274. PubMed ID: 28607447
[TBL] [Abstract][Full Text] [Related]
38. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.
Ji F; Zhang ZH; Zhang Y; Shen SL; Cao QH; Zhang LJ; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2018 Apr; 18(1):460. PubMed ID: 29690860
[TBL] [Abstract][Full Text] [Related]
39. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
40. circZFR promotes cell proliferation and migration by regulating miR-511/AKT1 axis in hepatocellular carcinoma.
Yang X; Liu L; Zou H; Zheng YW; Wang KP
Dig Liver Dis; 2019 Oct; 51(10):1446-1455. PubMed ID: 31147216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
